Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 137   

Articles published

NVO 54.74 +0.14 (0.26%)
price chart
Novo Nordisk A/S (ADR) Application For Insulin Drug Tresiba Accepted By FDA
Novo Nordisk A/S (ADR) (NYSE:NVO) has yet another victory to add to its long established success story in the diabetes market.
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.
Novo Nordisk's Saxenda Gets EU Approval for Obesity - Analyst Blog  Nasdaq
Novo Nordisk A/S (ADR) 0.4% Potential Upside Indicated yesterday by Leerink ...
Novo Nordisk A/S (ADR) using SYMBOL/TICKER code NYSE:NVO had its stock rating noted as 'Initiated' with the recommendation being set at 'MKT PERFORM' yesterday by analysts at Leerink Partners.
Novo Nordisk (ADR) (NYSE:NVO) Coverage Started by Analysts at Leerink Swann ...
Colgate-Palmolive Company (CL), Novo Nordisk A/S (ADR) (NVO) Among Billionaire ...
The quantitative hedge fund Renaissance Technologies, formerly managed by billionaire Jim Simons, has been so successful that it has been partly responsible for prompting other funds to begin the process of looking into and setting up their own ...
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate-Palmolive ...
Another major hedge fund that recently disclosed its long equity positions for the second quarter of 2014 is Jim Simons' Renaissance Technologies, one of the best performing firms in the sector.
Novo Nordisk A/S (ADR) (NYSE:NVO) close to 52-week high, short interest surging
Novo Nordisk A/S (ADR) (NYSE:NVO) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $56.27, up by 1.22%, with a volume of 1,155,117 shares against an average volume for the last 3 months of 1,713,340.
Buy Or Sell these Stocks? Novo Nordisk A/S (ADR) (NYSE:NVO), TherapeuticsMD ...
The Analyst Stock Recommendations are determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, Underperform or Sell.
Analyst Recommendation BUY: LKQ Corporation (NASDAQ:LKQ), Novo Nordisk A/S ...
Novo Nordisk A/S (ADR) (NYSE:NVO) lost -0.05% and closed in the last trading session at $55.00. The 52-Week range of the stock is $41.72 - $60.34.